Savara (SVRA) Short term Debt (2015 - 2022)
Savara (SVRA) reported Short term Debt of $12.5 million for Q1 2022, up 50.01% quarter-over-quarter from $8.3 million in Q4 2021.
Savara (SVRA) Short term Debt (2015 - 2022) Analysis & Trends
Savara (SVRA) has 7 years of Short term Debt data on file, last reported at $12.5 million in Q1 2022.
- Short term Debt for Q1 2022 came in at $12.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was $12.5 million (changed N/A YoY), and the FY2021 annual result was $8.3 million, changed N/A from the prior year.
- Short term Debt grew to $12.5 million in Q1 2022 per SVRA's latest filing, from $8.3 million in the prior quarter.
- Over five years, Short term Debt peaked at $12.5 million in Q1 2022 and troughed at $1.9 million in Q2 2018.
- A 4-year average of $5.4 million and a median of $4.0 million in 2018 frame the typical range for Short term Debt.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 12.50 Mn |
| Dec 31, 2021 | 8.33 Mn |
| Sep 30, 2021 | 4.17 Mn |
| Dec 31, 2019 | 2.00 Mn |
| Sep 30, 2018 | 3.75 Mn |
| Jun 30, 2018 | 1.88 Mn |
| Mar 31, 2017 | 1.58 Mn |
| Dec 31, 2016 | 1.55 Mn |
| Sep 30, 2016 | 11.59 Mn |
| Jun 30, 2016 | 12.51 Mn |
| Mar 31, 2016 | 11.45 Mn |
| Dec 31, 2015 | 10.99 Mn |
| Sep 30, 2015 | 1.54 Mn |